Evaluation of [123I] beta-CIT binding with SPECT in controls, early and late Parkinson's disease

Nucl Med Biol. 1995 Nov;22(8):985-91. doi: 10.1016/0969-8051(95)02020-9.


The main neuropathological feature in Parkinson's disease (PD) is a severe degeneration of the dopaminergic neurons in the substantia nigra resulting in a loss of dopamine in the striatum. Recently, a new radioligand (beta-CIT) for single photon emission computed tomography (SPECT) became available for in vivo imaging of the dopamine transporter on nerve endings of dopaminergic neurons in the striatum. The present results demonstrate that [123I]-beta-CIT SPECT allows a discrimination between early and late PD patients. In our opinion, these preliminary data suggest that [123I]-beta-CIT SPECT should be used from now on in longitudinal studies (such as the DATATOP study) in which the effects of (putative) neuroprotective interventions in PD are monitored.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Brain / diagnostic imaging
  • Brain / metabolism
  • Caudate Nucleus / diagnostic imaging
  • Caudate Nucleus / metabolism
  • Cocaine / analogs & derivatives*
  • Cocaine / pharmacokinetics
  • Disease Progression
  • Dopamine Agents* / pharmacokinetics
  • Female
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Parkinson Disease / diagnostic imaging*
  • Parkinson Disease / metabolism
  • Putamen / diagnostic imaging
  • Putamen / metabolism
  • Tomography, Emission-Computed, Single-Photon


  • Dopamine Agents
  • 2beta-carbomethoxy-3beta-(4-iodophenyl)tropane
  • Cocaine